Top

BMC Cancer

Published in:

01-12-2020 | Pituitary Adenoma | Research article

The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma

Authors: Marius Treutwein, Felix Steger, Rainer Loeschel, Oliver Koelbl, Barbara Dobler

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

This planning study compares different radiotherapy techniques for patients with pituitary adenoma, including flatness filter free mode (FFF), concerning plan quality and secondary malignancies for potentially young patients. The flatness filter has been described as main source of photon scatter.

Material and methods

Eleven patients with pituitary adenoma were included. An Elekta Synergy™ linac was used in the treatment planning system Oncentra® and for the measurements. 3D plans, IMRT, and VMAT plans and non-coplanar varieties were considered. The plan quality was evaluated regarding homogeneity, conformity, delivery time and dose to the organs at risk. The secondary malignancy risk was calculated from dose volume data and from measured dose to the periphery using different models for carcinoma and sarcoma risk.

Results

The homogeneity and conformity were nearly unchanged with and without flattening filter, neither was the delivery time found substantively different. VMAT plans were more homogenous, conformal and faster in delivery than IMRT plans. The secondary cancer risk was reduced with FFF both in the treated region and in the periphery. VMAT plans resulted in a higher secondary brain cancer risk than IMRT plans, but the risk for secondary peripheral cancer was reduced. Secondary sarcoma risk plays a minor role. No advantage was found for non-coplanar techniques. The FFF delivery times were not shortened due to additional monitor units needed and technical limitations. The risk for secondary brain cancer seems to depend on the irradiated volume. Secondary sarcoma risk is much smaller than carcinoma risk in accordance to the results of the atomic bomb survivors. The reduction of the peripheral dose and resulting secondary malignancy risk for FFF is statistically significant. However, it is negligible in comparison to the risk in the treated region.

Conclusion

Treatments with FFF can reduce secondary malignancy risk while retaining similar quality as with flattening filter and should be preferred. VMAT plans show the best plan quality combined with lowest peripheral secondary malignancy risk, but highest level of second brain cancer risk. Taking this into account VMAT FFF seems the most advantageous technique for the treatment of pituitary adenomas with the given equipment.

van den Bergh ACM, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys. 2007;67:863–9. https://doi.org/10.1016/j.ijrobp.2006.09.049.CrossRefPubMed

Erridge SC, Conkey DS, Stockton D, Strachan MWJ, Statham PFX, Whittle IR, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009;93:597–601. https://doi.org/10.1016/j.radonc.2009.09.011 CrossRefPubMed

Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336:172–7. https://doi.org/10.1056/NEJM199701163360303.CrossRefPubMed

Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly: is there still a place for radiotherapy? Pituitary. 2007;10:53–9. https://doi.org/10.1007/s11102-007-0002-5.CrossRefPubMed

Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JAH. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006;91:1239–45. https://doi.org/10.1210/jc.2005-1616.CrossRefPubMed

Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi ER. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neuro-Oncol. 2007;84:79–84. https://doi.org/10.1007/s11060-007-9344-0.CrossRef

Snead FE, Amdur RJ, Morris CG, Mendenhall WM. Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys. 2008;71:994–8. https://doi.org/10.1016/j.ijrobp.2007.11.057.CrossRefPubMed

Chae S-M, Lee KW, Son SH. Dosimetric impact of multileaf collimator leaf width according to sophisticated grade of technique in the IMRT and VMAT planning for pituitary adenoma lesion. Oncotarget. 2016;7:78119–26. https://doi.org/10.18632/oncotarget.12974.CrossRefPubMedPubMedCentral

Lamiman K, Wong KK, Tamrazi B, Nosrati JD, Olch A, Chang EL, Kiehna EN. A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications. Neurosurg Focus. 2016;41:E15. https://doi.org/10.3171/2016.9.FOCUS16298.CrossRefPubMed

10.

Minniti G, Osti MF, Niyazi M. Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol. 2016;11:1–14. https://doi.org/10.1186/s13014-016-0710-y.CrossRef

11.

Georg D, Knöös T, McClean B. Current status and future perspective of flattening filter free photon beams. Med Phys. 2011;38:1280–93. https://doi.org/10.1118/1.3554643.CrossRefPubMed

12.

Alvarez Moret J, Obermeier T, Pohl F, Loeschel R, Koelbl O, Dobler B. Second cancer risk after radiation therapy of ependymoma using the flattening filter free irradiation mode of a linear accelerator. J Appl Clin Med Phys. 2018;19:632–9. https://doi.org/10.1002/acm2.12438.CrossRefPubMedPubMedCentral

13.

Bell K, Dzierma Y, Palm J, Nuesken F, Licht N, Rube C. mARC prostate treatment planning with Varian eclipse for flat vs. FFF beams Phys Med. 2016;32:474–8. https://doi.org/10.1016/j.ejmp.2016.02.011.CrossRefPubMed

14.

Dobler B, Maier J, Knott B, Maerz M, Loeschel R, Koelbl O. Second cancer risk after simultaneous integrated boost radiation therapy of right sided breast cancer with and without flattening filter. Strahlenther Onkol. 2016. https://doi.org/10.1007/s00066-016-1025-5.CrossRef

15.

Dobler B, Obermeier T, Hautmann MG, Khemissi A, Koelbl O. Simultaneous integrated boost therapy of carcinoma of the hypopharynx/larynx with and without flattening filter - a treatment planning and dosimetry study. Radiat Oncol. 2017;12:114. https://doi.org/10.1186/s13014-017-0850-8.CrossRefPubMedPubMedCentral

16.

Maier J, Knott B, Maerz M, Loeschel R, Koelbl O, Dobler B. Simultaneous integrated boost (SIB) radiation therapy of right sided breast cancer with and without flattening filter - a treatment planning study. Radiat Oncol. 2016;11:111. https://doi.org/10.1186/s13014-016-0687-6.CrossRefPubMedPubMedCentral

17.

Murray LJ, Thompson CM, Lilley J, Cosgrove V, Franks K, Sebag-Montefiore D, Henry AM. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol. 2015;60:1237–57. https://doi.org/10.1088/0031-9155/60/3/1237.CrossRefPubMed

18.

Treutwein M, Hipp M, Koelbl O, Dobler B. Volumetric-modulated arc therapy and intensity-modulated radiation therapy treatment planning for prostate cancer with flattened beam and flattening filter free linear accelerators. J Appl Clin Med Phys. 2017;18:307–14. https://doi.org/10.1002/acm2.12168.CrossRefPubMedPubMedCentral

19.

Petersenn S, Lüdecke DK, Fahlbusch R, Renner U, Buchfelder M, Wowra B, Saeger W. Therapie von Hypophysentumoren. Dtsch Arztebl Int. 2006;103:A-474.

20.

McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA. Demographic differences in incidence for pituitary adenoma. Pituitary. 2011;14:23–30. https://doi.org/10.1007/s11102-010-0253-4.CrossRefPubMedPubMedCentral

21.

Paynter D, Weston SJ, Cosgrove VP, Evans JA, Thwaites DI. Beam characteristics of energy-matched flattening filter free beams. Med Phys. 2014;41:52103. https://doi.org/10.1118/1.4871615.CrossRef

22.

Treutwein M, Härtl PM, Gröger C, Katsilieri Z, Dobler B. Linac twins in radiotherapy. In: Nenoi M, editor. Evolution of: Ionizing Radiation Research. London: InTech; 2015. https://doi.org/10.5772/60427.

23.

Treutwein M, Hipp M, Kölbl O, Bogner L. IMRT of prostate cancer. Strahlenther Onkol. 2009;185:379–83. https://doi.org/10.1007/s00066-009-1950-7.CrossRefPubMed

24.

Morales-Paliza MA, Coffey CW, Ding GX. Evaluation of the dynamic conformal arc therapy in comparison to intensity-modulated radiation therapy in prostate, brain, head-and-neck and spine tumors. J Appl Clin Med Phys. 2011;12:5–19.CrossRef

25.

RTOG. RTOG | Clinical Trials | Study Number 0225. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0225. Accessed 6 Nov 2018.

26.

Scoccianti S, Detti B, Gadda D, Greto D, Furfaro I, Meacci F, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist's guide for delineation in everyday practice. Radiother Oncol. 2015;114:230–8. https://doi.org/10.1016/j.radonc.2015.01.016.CrossRefPubMed

27.

Treutwein M, Hipp M, Kölbl O, Dobler B. Ein neuer Typ von Dose-Volume-Objectives bei der VMAT-Planung von Patienten mit Prostatakarzinom: Surrounding Dose Fall-Off. In: Georg D, editor. Wien; 2011. p. 126–127.

28.

Bzdusek K, Friberger H, Eriksson K, Hardemark B, Robinson D, Kaus M. Development and evaluation of an efficient approach to volumetric arc therapy planning. Med Phys. 2009;36:2328–39. https://doi.org/10.1118/1.3132234.CrossRefPubMed

29.

Sun W-Z, Chen L, Yang X, Wang B, Deng X-W, Huang X-Y. Comparison of treatment plan quality of VMAT for esophageal carcinoma with: flattening filter beam versus flattening filter free beam. J Cancer. 2018;9:3263–8. https://doi.org/10.7150/jca.26044.CrossRefPubMedPubMedCentral

30.

ICRU. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT): contents. J ICRU. 2010;10:1–106.

31.

Williams G, Tobler M, Leavitt D. Pitfalls in normalization for intensity-modulated radiation therapy planning. Med Dosim. 2005;30:194–200. https://doi.org/10.1016/j.meddos.2005.06.003.CrossRefPubMed

32.

Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93(Suppl 3):219–22. https://doi.org/10.3171/jns.2000.93.supplement.CrossRefPubMed

33.

Kragl G, Baier F, Lutz S, Albrich D, Dalaryd M, Kroupa B, et al. Flattening filter free beams in SBRT and IMRT: dosimetric assessment of peripheral doses. Z Med Phys. 2011;21:91–101. https://doi.org/10.1016/j.zemedi.2010.07.003.CrossRefPubMed

34.

Sarkar V, Huang L, Huang Y-HJ, Szegedi MW, Rassiah-Szegedi P, Zhao H, Salter BJ. Head to head comparison of two commercial phantoms used for SRS QA. J Radiosurgery and SBRT. 2016;4:213–23.

35.

Bogner L, Scherer J, Treutwein M, Hartmann M, Gum F, Amediek A. Verification of IMRT: techniques and problems. Strahlenther Onkol. 2004;180:340–50. https://doi.org/10.1007/s00066-004-1219-0.CrossRefPubMed

36.

Dobler B, Streck N, Klein E, Loeschel R, Haertl P, Koelbl O. Hybrid plan verification for intensity-modulated radiation therapy (IMRT) using the 2D ionization chamber array I’mRT MatriXX - a feasability study. Phys Med Biol. 2010;55:N39–55.CrossRef

37.

van Esch A, Basta K, Evrard M, Ghislain M, Sergent F, Huyskens DP. The Octavius1500 2D ion chamber array and its associated phantoms: Dosimetric characterization of a new prototype. Med Phys. 2014;41:91708. https://doi.org/10.1118/1.4892178.CrossRef

38.

Low DA, Harms WB, Mutic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25:656–61. https://doi.org/10.1118/1.598248.CrossRefPubMed

39.

Ezzell GA, Burmeister JW, Dogan N, LoSasso TJ, Mechalakos JG, Mihailidis D, et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM task group 119. Med Phys. 2009;36:5359–73. https://doi.org/10.1118/1.3238104.CrossRefPubMed

40.

Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model. 2011;8:1–27. https://doi.org/10.1186/1742-4682-8-27.CrossRef

41.

Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007;168:1–64. https://doi.org/10.1667/RR0763.1.CrossRefPubMed

42.

Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–94. https://doi.org/10.1200/JCO.2002.09.038.CrossRefPubMed

43.

Yamanaka R, Abe E, Sato T, Hayano A, Takashima Y. Secondary intracranial tumors following radiotherapy for pituitary adenomas: a systematic review. Cancers (Basel). 2017. https://doi.org/10.3390/cancers9080103.CrossRef

44.

Jiang X, Liu Z, Huang X, Wang H, Zhao H. Extended endoscopic endonasal approach for pituitary adenoma: a single-center experience of 171 patients. Chin Neurosurg Jl. 2017;3:613. https://doi.org/10.1186/s41016-017-0080-9.CrossRef

45.

Faul F, Erdfelder E, Lang A-G, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91. https://doi.org/10.3758/BF03193146.CrossRef

46.

Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60. https://doi.org/10.3758/BRM.41.4.1149.CrossRefPubMed

47.

Bender R, Lange S. Adjusting for multiple testing--when and how? J Clin Epidemiol. 2001;54:343–9.CrossRef

48.

Goldsmith BJ, Rosenthal SA, Wara WM, Larson DA. Optic neuropathy after irradiation of meningioma. Radiology. 1992;185:71–6. https://doi.org/10.1148/radiology.185.1.1523337.CrossRefPubMed

49.

Dobler B, Khemissi A, Obermeier T, Hautmann MG, Katsilieri Z, Kölbl O. Re-irradiating spinal column metastases using IMRT and VMAT with and without flattening filter - a treatment planning study. Radiat Oncol. 2016;11:1280. https://doi.org/10.1186/s13014-016-0603-0.CrossRef

Title: The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma
Authors: Marius Treutwein
Felix Steger
Rainer Loeschel
Oliver Koelbl
Barbara Dobler
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Pituitary Adenoma
Radiotherapy
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-6535-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway

Fast growing angiosarcoma of the right atrium after radiofrequency catheter ablation: a missed diagnosis or misdiagnosis case report

Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment

Simultaneous occurrence of invasive pulmonary aspergillosis and diffuse large B-cell lymphoma: case report and literature review

Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer